Atom | Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Due Dates: January 27, 2025 | April 18, 2025 (AIDS) | July 15, 2025 | January 15, 2026 | July 15, 2026

Funding Amounts: No budget limit; up to 1 year for UG3 (preparatory) phase, up to 4 years for UH3 (implementation) phase (max 5 years total); actual award size based on project needs.

Summary: Supports small molecule drug discovery and development for nervous system disorders, enabling academic and industry researchers to advance candidates toward clinical testing with NIH and CRO collaboration.

Key Information: Applicants retain IP rights; both clinical trial and non-clinical trial projects are eligible; foreign organizations may apply.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Sign in to see full grant listing